Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)

Epilepsy Research

Volumn 111, Issue , 2015, Pages 85-141

  Bialer, Meir ^a   Johannessen, Svein I ^b   Levy, René H ^c,d   Perucca, Emilio ^e,f   Tomson, Torbjörn ^g   White, H Steve ^h  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PAVIA   (Italy)

^f C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^g KAROLINSKA INSTITUTE   (Sweden)

^h UNIVERSITY OF UTAH   (United States)

Author keywords

Antiepileptic drugs; Clinical trials; Conference; Drug development; Epilepsy; Pharmacology

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ACETAMIDE DERIVATIVE; ADENOSINE; ADENOSINE RELEASING SILK; AMP X 0079; ANTICONVULSIVE AGENT; BRIVARACETAM; BUMETANIDE; CANNABIDIOL; CANNABIDIOL DERIVATIVE; CANNABIDIVARIN; DEOXYGLUCOSE; EVEROLIMUS; GALANIN DERIVATIVE; GANAXOLONE; HUPERZINE A; IMEPITOIN; MINOCYCLINE; N [3 [4 [4 CYCLOHEXYL METHANESULFONYLAMINO BUTYL] PIPERAZIN 1 YL] PHENYL]ACETAMIDE DIHYDROCHLORIDE; NAX 810 2; NEW DRUG; PITOLISANT; PLACEBO; SAGE 217; SEC BUTYL PROPYLACETAMIDE; SEROTONIN 1A AGONIST; SILK; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALNOCTAMIDE; DELAYED RELEASE FORMULATION;

ALZHEIMER DISEASE; ARTICLE; BACKACHE; BEHAVIOR DISORDER; BLURRED VISION; BURNING SENSATION; CHOLECYSTITIS; COGNITIVE DEFECT; DECREASED APPETITE; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG IMPLANT; DRUG METABOLISM; DRUG POTENTIATION; DRUG RELEASE; DRUG STRUCTURE; DYSPNEA; EPILEPSY; EPILEPTIC STATE; EYE MOVEMENT DISORDER; FATIGUE; FIBROMYALGIA; FOCAL EPILEPSY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPIGMENTATION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOCHLOREMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INCREASED APPETITE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INSOMNIA; INTRACRANIAL HYPERTENSION; LIMB PAIN; MANIA; MEMORY DISORDER; METALLIC TASTE; MIGRAINE; MUSCLE CRAMP; MYCOSIS; MYOCLONUS SEIZURE; NAUSEA; NAUSEA AND VOMITING; NECK PAIN; NEUROLOGIST; NONHUMAN; OTOTOXICITY; PARESTHESIA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; SCIENTIST; SEIZURE; SINGLE DRUG DOSE; SKIN MANIFESTATION; SKIN TINGLING; SOMNOLENCE; SPAIN; STOMATITIS; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; THORAX PAIN; THROAT TIGHTNESS; TONIC CLONIC SEIZURE; TRAUMATIC EPILEPSY; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING; WEAKNESS; ADVERSE EFFECTS; ANIMAL; CLINICAL TRIAL (TOPIC); DELAYED RELEASE FORMULATION; DRUG DEVELOPMENT; ORGANIZATION; PHARMACOKINETICS; PHARMACOLOGY; RESEARCH; THERAPEUTIC USE;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DELAYED-ACTION PREPARATIONS; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; EPILEPSY; HUMANS; RESEARCH REPORT;

EID: 84924308270     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2015.01.001     Document Type: Review

References (221)

1. Abraham J., Fox P.D., Condello C., Bartolini A., Koh S. Minocycline attenuates microglia activation and blocks the long-term epileptogenic effects of early-life seizures. Neurobiol. Dis. 2012, 46:425-430.
2. Amada N., Yamasaki Y., Williams C.M., Whalley B.J. Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. Peer J. 2013, 1:e214.
3. Ames F.R., Cridland S. Anticonvulsant effects of cannabidiol. S. Afr. Med. J. 1986, 69:14. (Letter).
4. Aronica E., Sandau U.S., Iyer A., Boison D. Glial adenosine kinase - a neuropathological marker of the epileptic brain. Neurochem. Int. 2013, 63:688-695.
5. Bagdy G., Kecskemeti V., Riba P., Jakus R. Serotonin and epilepsy. J. Neurochem. 2007, 100:857-873.
6. Balgård M., Nyberg S., Spigset O., Andersson A., Porankiewicz-Asplund J., Purdy R.H., Zhu D., Bäckström T., Poromaa I.S. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl.) 2006, 186:414-424.
7. Beheshti Nasr S.M., Moghimi A., Mohammad-Zadeh M., Shamsizadeh A., Noorbakhsh S.M. The effect of minocycline on seizures induced by amygdala kindling in rats. Seizure 2013, 22:670-674.
8. Belelli D., Bolger M.B., Gee K.W. Anticonvulsant profile of the progesterone metabolite 5 alpha-pregnan-3 alpha-ol-20-one. Eur. J. Pharmacol. 1989, 166:325-329.
9. A receptor. Nat. Rev. Neurosci. 2005, 6:565-575.
10. A receptors of thalamocortical neurons: a molecular target for hypnotics. J. Neurosci. 2005, 25:11513-11520.
11. Ben-Ari Y., Khalilov I., Kahle K.T., Cherubini E. The GABA excitatory/inhibitory shift in brain maturation and neurological disorders. Neuroscientist 2012, 18:467-486.
12. Bersudsky Y., Applebaum Y., Sharony A., Mishory A., Poderbeasky A., Agam G., Belmaker R.H. Valnoctamide as valproate substitute with low teratogenic potential in mania: double blind controlled clinical trial. Bipolar Disord. 2010, 12:376-382.
13. Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv. Drug Deliv. Rev. 2012, 64:887-895.
14. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 2010, 92:89-124.
15. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. 1999, 34:1-41.
16. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 2001, 43:11-58.
17. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 2013, 103:2-30.
18. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009, 83:1-43.
19. Bialer M., White H.S. Key factors in the discovery and development of new antiepileptic drugs (AEDs). Nat. Rev. Drug Discov. 2010, 9:68-83.
20. Bialer M., Yagen B. Valproic acid - second generation. Neurotherapeutics 2007, 4:130-137.
21. Bisogno T., Howell F., Williams G., Minassi A., Cascio M.G., Ligresti A., Matias I., Schiano-Moriello A., Paul P., Williams E.J., Gangadharan U., Hobbs C., Di Marzo V., Doherty P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 2003, 163:463-468.
22. Biton V., Berkovic S.F., Abou-Khalil B., Sperling M.R., Johnson M.E., Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014, 55:57-66.
23. A receptor. Brain Res. 1991, 561:157-161.
24. Boison D. Adenosine augmentation therapy for epilepsy. Jasper's Basic Mechanisms of the Epilepsies 2012, 1150-1160. Oxford University Press, Oxford. J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta (Eds.).
25. Boison D. Adenosine as a modulator of brain activity. Drug News Perspect. 2007, 20:607-611.
26. Boison D. Adenosine kinase: exploitation for therapeutic gain. Pharmacol. Rev. 2013, 65:906-943.
27. Bordelon N.R., Koester A.J., Arndt T.P., Hong S.P., Brys A.M., Sutula T.P., Joshi P.S., Terse P.S. Subchronic (45 day) oral toxicity study of 2-deoxy-d-glucose (2-DG) in F344 rats with a 15 day recovery period. Int. J. Toxicol. 2013, 33:66.
28. Brodsky A., Costantini C., von Rosenstiel P. Safety and tolerability of brivaracetam (ucb 34714) as adjunctive treatment in adults with refractory partial-onset seizures. Epilepsia 2007, 48(Suppl. 6):342.
29. Broomall E., Natale J.E., Grimason M., Goldstein J., Smith C.M., Chang C., Kanes S., Rogawski M.A., Wainwright M.S. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann. Neurol. 2014, 76:911-915.
30. Carlini E.A., Cunha J.M. Hypnotic and antiepileptic effects of cannabidiol. J. Clin. Pharmacol. 1981, 21:417S-427S.
31. A receptor. J. Pharmacol. Exp. Ther. 1997, 280:1284-1295.
32. Casha S., Zygun D., McGowan M.D., Bains I., Yong V.W., Hurlbert R.J. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain 2012, 135:1224-1236.
33. Cech C., Hanson M., Ting L., Mulvey B., Langberg T., Hutchinson E., Rutecki P., Sutula T.P. Subtle seizures after TBI in a unique strain of kindling-susceptible rats: electrographic, behavioral, and phenotypic features. Poster 1.027 American Epilepsy Society 2012, http://www.aesnet.org/.
34. Chen J.F., Eltzschig H.K., Fredholm B.B. Adenosine receptors as drug targets - what are the challenges?. Nat. Rev. Drug Discov. 2013, 12:265-286.
35. Clark R.H., Bloom B.T., Spitzer A.R., Gerstmann D.R. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006, 117:1979-1987.
36. 35S]-TBPS binding in the brain of rats exposed to isoniazid, pentylenetetrazol or stress. Br. J. Pharmcol. 1996, 118:839-846.
37. Costantino L., Barlocco D. Privileged structures as leads in medicinal chemistry. Curr. Med. Chem. 2006, 13:65-85.
38. Curatolo P., Moavero R. mTOR inhibitors as a new therapeutic option for epilepsy. Expert Rev. Neurother. 2013, 13:627-638.
39. Curatolo P., Moavero R. mTOR inhibitors in tuberous sclerosis complex. Curr. Neuropharmacol. 2012, 10:404-415.
40. Dancey J.E. Inhibitors of the mammalian target of rapamycin. Expert Opin. Investig. Drugs 2005, 14:313-328.
41. De Petrocellis L., Ligresti A., Moriello A.S., Allara M., Bisogno T., Petrosino S., Stott C.G., Di Marzo V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 2011, 163:1479-1494.
42. De Petrocellis L., Orlando P., Moriello A.S., Aviello G., Stott C., Izzo A.A., Di Marzo V. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol. (Oxford) 2012, 294:255-266.
43. Deiana S., Watanabe A., Yamasaki Y., Amada N., Arthur M., Fleming S., Woodcock H., Dorward P., Pigliacampo B., Close S., Platt B., Riedel G. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Delta(9)-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) 2012, 219:859-873.
44. DeSimone R.W., Currie K.S., Mitchell S.A., Darrow J.W., Pippin D.A. Privileged structures: applications in drug discovery. Comb. Chem. High Throughput Screen. 2004, 7:473-494.
45. Detrait E.R., Leclercq K., Loscher W., Potschka H., Niespodziany I., Hanon E., Kaminski R.M., Matagne A., Lamberty Y. Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats. Epilepsy Res. 2010, 91:74-83.
46. Devinsky O., Cilio R., Cross H., Fernandez-Ruiz J., French J., Hill C., Katz R., Di Marzo V., Jutras-Aswad D., Notcutt W.G., Martinez-Orgado J., Robson P.J., Rohrback B.G., Thiele E., Whalley B., Friedman D. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014, 55:791-802.
47. Drevets W.C., Thase M.E., Moses-Kolko E.L., Price J., Frank E., Kupfer D.J., Mathis C. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl. Med. Biol. 2007, 34:865-877.
48. Drutel G., Peitsaro N., Karlstedt K., Wieland K., Smit M.J., Timmerman H., Panula P., Leurs R. Identification of rat H3 receptor isoforms with different brain expression and signalling properties. Mol. Pharmacol. 2001, 59:1-8.
49. Duarte C.D., Barreiro E.J., Fraga C.A. Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev. Med. Chem. 2007, 7:1108-1119.
50. Dzhala V.I., Talos D.M., Sdrulla D.A., Brumback A.C., Mathews G.C., Benke T.A., Delpire E., Jensen F.E., Staley K.J. NKCC1 transporter facilitates seizures in the developing brain. Nat. Med. 2005, 11:1205-1213.
51. Eftekhari S., Mehvari Habibabadi J., Najafi Ziarani M., Hashemi Fesharaki S.S., Gharakhani M., Mostafavi H., Joghataei M.T., Beladimoghadam N., Rahimian E., Hadjighassem M.R. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. Epilepsia 2013, 54:9-12.
52. Ellenbroek B.A., Ghiabi B. The other side of the histamine H3 receptor. Trends Neurosci. 2014, 37:191-199.
53. Elman I., Sokoloff L., Adler C.M., Weisenfeld N., Brier A. The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteers. Brain Res. 1999, 815:243-249.
54. Favale E., Rubino V., Mainardi P., Lunardi G., Albano C. Anticonvulsant effect of fluoxetine in humans. Neurology 1995, 45:1926-1927.
55. French J.A., Costantini C., Brodsky A., von Rosenstiel P. Adjunctive brivaracetam for refractory partial-onset seizures. A randomized, controlled trial. Neurology 2010, 75:519-525.
56. Garrido-Mesa N., Zarzuelo A., Galvez J. Minocycline: far beyond an antibiotic. Br. J. Pharmacol. 2013, 169:337-352.
57. Garriga-Canut M., Schoenike B., Qazi R., Bergendahl K., Daley T.J., Pfender R., Morrison J.F., Ockuly J., Stafstrom C., Sutula T., Roopra A. 2-Deoxy-d-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat. Neurosci. 2006, 9:1382-1387.
58. Gasior M., Yankura J., Hartman A.L., French A., Rogawski M. Anticonvulsant and proconvulsant actions of 2-deoxy-d-glucose. Epilepsia 2010, 51:1385-1394.
59. Gedde A.A., Maa E. Whole cannabis extract of high concentration cannabidiol may calm seizures in highly refractory pediatric epilepsies. American Epilepsy Society Annual Meeting, 3.330 2013.
60. Gemkow M.J., Davenport A.J., Harich S., Ellenbroek B.A., Cesura A., Hallett D. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov. Today 2009, 14:509-515.
61. Gillard M., Fuks B., Leclercq K., Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur. J. Pharmacol. 2011, 664:36-44.
62. Gloss D., Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst. Rev. 2012, 6(June):CD009270.
63. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., Hilton J.F., Spitalny G.M., MacArthur R.B., Mitsumoto H., Neville H.E., Boylan K., Mozaffar T., Belsh J.M., Ravits J., Bedlack R.S., Graves M.C., McCluskey L.F., Barohn R.J., Tandan R. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007, 6:1045-1053.
64. Granik V., Antonova S., Toumi M., Bakhutashvili A. Beprodone a new potent antiepileptic compound phase I and IIa studies. 13th European Conference on Epilepsy & Society 2013, (Abstract).
65. Greydanus D.E., Hawver E.K., Greydanus M.M., Merrick J. Marijuana: current concepts. Front. Public Health 2013, 1:42.
66. Grossel S.S., Crowl D.A. Handbook of Highly Toxic Materials Handling and Management 1995, Marcel Dekker, New York.
67. Gyermek L., Iriarte J., Crabbé P. Steroids. CCCX. Structure-activity relationship of some steroidal hypnotic agents. J. Med. Chem. 1968, 11:117-125.
68. Halstenson C.E., Matzke G.R. Bumetanide: a new loop diuretic (Bumex, Roche Laboratories). Drug Intell. Clin. Pharm. 1983, 17:786-797.
69. Hasler G., Bonwetsch R., Giovacchini G., Toczek M.T., Bagic A., Luckenbaugh D.A., Drevets W.C., Theodore W.H. 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol. Psychiatry 2007, 62:1258-1264.
70. Hen N., Shekh-Ahmad T., Yagen B., McDonough J.H., Finnell R.H., Wlodarczyk B., Bialer M. Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. J. Med. Chem. 2013, 56:6467-6477.
71. Heo K., Cho Y.J., Cho K.J., Kim H.W., Kim H.J., Shin H.Y., Lee B.I., Kim G.W. Minocycline inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice. Neurosci. Lett. 2006, 398:195-200.
72. A receptors. Pharmacol. Ther. 2007, 116:20-34.
73. Hill A.J., Jones N.A., Williams C.M., Stephens G.J., Whalley B.J. Development of multi-electrode array screening for anticonvulsants in acute rat brain slices. J. Neurosci. Methods 2010, 185:246-256.
74. Hill A.J., Mercier M.S., Hill T.D., Glyn S.E., Jones N.A., Yamasaki Y., Futamura T., Duncan M., Stott C.G., Stephens G.J., Williams C.M., Whalley B.J. Cannabidivarin is anticonvulsant in mouse and rat. Br. J. Pharmacol. 2012, 167:1629-1642.
75. Hill A.J., Williams C.M., Whalley B.J., Stephens G.J. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol. Ther. 2012, 133:79-97.
76. Hill T.D., Cascio M.G., Romano B., Duncan M., Pertwee R.G., Williams C.M., Whalley B.J., Hill A.J. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br. J. Pharmacol. 2013, 170:679-692.
77. Hochman D.W. The extracellular space and epileptic activity in the adult brain: explaining the antiepileptic effects of furosemide and bumetanide. Epilepsia 2012, 53(Suppl. 1):18-25.
78. A receptors through two discrete transmembrane sites. Nature 2006, 444:486-489.
79. Huntington Study Group Minocycline safety and tolerability in Huntington disease. Neurology 2004, 63:547-549.
80. Hutchinson E., Rutecki P., Meyerand M.E., Sutula T. MRI and DTI markers for TBI-related brain tissue damage and plasticity in a rat CCI model demonstrate protective effects of 2DG. Poster 356.9 2010, http://www.sfn.org/.
81. Hutchinson E., Rutecki P., Meyerand E., Sutula T. Quantitative manganese-enhanced MRI detection of differences between kindling-susceptible and kindling-resistant strains of rats. Poster 404.03 Soc. Neurosci. Abstr. 2012, http://www.sfn.org/.
82. Inocente C., Arnulf I., Bastuji H., Thibault-Stoll A., Raoux A., Reimão R., Lin J.S., Franco P. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin. Neuropharmacol. 2012, 35:55-60.
83. Iyer G.R., John F., Reinhard J.F., Oshana S., Kauffman M., Donahue S. Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects. J. Clin. Pharmacol. 2007, 47:817-824.
84. Izzo A.A., Borrelli F., Capasso R., Di Marzo V., Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 2009, 30:515-527.
85. Jones N.A., Hill A.J., Smith I., Bevan S.A., Williams C.M., Whalley B.J., Stephens G.J. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J. Pharmacol. Exp. Ther. 2010, 332:569-577.
86. Jones N.A., Glynn S.E., Akiyaman S., Hill T.D.M., Hill A.J., Weston S.E., Burnett M.D.A., Yamasaki Y., Stephens G.J., Whalley B.J., Williams C.M. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012, 21:344-352.
87. Joshi S., Rajasekaran K., Kapur J. GABAergic transmission in temporal lobe epilepsy: the role of neurosteroids. Exp. Neurol. 2011, 244:36-42.
88. - cotransporter NKCC1. J Child Neurol.; 2009, 24:572-576.
89. Kaminski R.M., Livingood M.R., Rogawski M.A. Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia 2004, 45:864-867.
90. Kask K., Bäckström T., Lundgren P., Sundström Poromaa I. Allopregnanolone has no effect on startle response and prepulse inhibition of startle response in patients with premenstrual dysphoric disorder or healthy controls. Pharmacol. Biochem. Behav. 2009, 92:608-613.
91. Kask K., Bäckström T., Nilsson L.G., Sundström-Poromaa I. Allopregnanolone impairs episodic memory in healthy women. Psychopharmacology (Berl) 2008, 199:161-168.
92. Kasteleijn-Nolst Trenité D., Parain D., Genton P., Masnou P., Schwartz J.C., Hirsch E. Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: dose-dependent effects in the human photosensitivity model. Epilepsy Behav. 2013, 28:66-70.
93. Kenda B.M., Matagne A.C., Talaga P.E., Pasau P.M., Differding E., Lallemand B.I., Frycia A.M., Moureau F.G., Klitgaard H.V., Gillard M.R., Fuks B., Michel P. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J. Med. Chem. 2004, 47:530-549.
94. Kerrigan J.F., Shields W.D., Nelson T.Y., Bluestone D.L., Dodson W.E., Bourgeois B.F., Pellock J.M., Morton L.D., Monaghan E.P. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res. 2000, 42:133-139.
95. Kirchner G.I., Meier-Wiedenbach I., Manns M.P. Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. 2004, 43:83-95.
96. Kiviranta T., Tuomisto L., Airaksinen E.M. Histamine in cerebrospinal fluid of children with febrile convulsions. Epilepsia 1995, 36:276-280.
97. Klein P., Biton V., Dilley D., Barnes M.L., Schiemann J., Lu Z.(S.) Safety/tolerability of adjunctive intravenous (IV) brivaracetam (BRV) as infusion or bolus in patients with epilepsy. Epilepsy Curr. 2014, 14(Suppl. s1):389.
98. Kokate T.G., Svensson B.E., Rogawski M.A. Anticonvulsant activity of neurosteroids: correlation with γ-aminobutyric acid-evoked chloride current potentiation. J. Pharmacol. Exp. Ther. 1994, 270:1223-1229.
99. Kokate T.G., Cohen A.L., Karp E., Rogawski M.A. Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice. Neuropharmacology 1996, 35:1049-1056.
100. Kovarik J.M., Beyer D., Schmouder R.L. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm. Drug Dispos. 2006, 27:421-426.
101. Krueger D.A., Care M.M., Holland K., Agricola C., Tudor P., Mangeshkar K.A., Wilson A., Byars T., Sahmoud T., Franz D.N. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 2010, 363:1801-1811.
102. Krueger D.A., Wilfong A.A., Holland-Bouley K., Anderson A.E., Agricola K., Tudor C., Mays M., Lopez C.M., Kim M.O., Franz D.N. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann. Neurol. 2013, 74:679-687.
103. Kwan P., Trinka E., Van P.W., Rektor I., Johnson M.E., Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014, 55:38-46.
104. A receptors. Prog. Neurobiol. 2003, 71:67-80.
105. Lang N., Rothkegel H., Terney D., Antal A., Paulus W. Minocycline exerts acute inhibitory effects on cerebral cortex excitability in humans. Epilepsy Res. 2013, 107:302-305.
106. Langberg T., Miller K., Stafstrom C.E., Sutula T.P. Unique strains of kindling-susceptible and kindling-resistant rats are behaviorally distinct: evidence background on both seizure-induced plasticity and behavior. Poster 447.03 Soc. Neurosci. Abstr. 2012, http://www.sfn.org/.
107. Laxer K., Blum D., Abou-Khalil B.W., Morrell M.J., Lee D.A., Data J.L., Monaghan E.P. Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Epilepsia 2000, 41:1187-1194. the Ganaxolone Presurgical Study Group.
108. Lehmkuhle M.J., Thomson K.E., Scheerlinck P., Pouliot W., Greger B., Dudek F.E. A simple quantitative method for analyzing electrographic status epilepticus in rats. J. Neurophysiol. 2009, 101:1660-1670.
109. Lian X.Y., Khan F.A., Stringer J.L. Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats. J. Neurosci. 2007, 27:12007-12011.
110. Lindskog S., Ahrén B. Galanin: effects on basal and stimulated insulin and glucagon secretion in the mouse. Acta Physiol. Scand. 1987, 129:305-309.
111. Lindskog S., Ahrén B. Effects of galanin on insulin and glucagon secretion in the rat. Int. J. Pancreatol. 1989, 4:335-344.
112. Lindskog S., Dunning B.E., Mårtensson H., Ar'Rajab A., Taborsky G.J., Ahrén B. Galanin of the homologous species inhibits insulin secretion in the rat and in the pig. Acta Physiol. Scand. 1990, 139:591-596.
113. Liou G., Auchampach J.A., Hillard C.J., Zhu G., Yousufzai B., Mian S., Khan S., Khalifa Y. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Invest. Ophthalmol. Vis. Sci. 2008, 49:5526-5531.
114. Liu E., Hepner A., Dilley D., Stockis A., Daniels A. Safety and tolerability of adjunctive brivaracetam administered as oral solution in pediatric patients aged at least 1 month to 16 years with epilepsy. Epilepsy Curr. 2014, 14(Suppl. s1):390-391.
115. Liu Y., Shangguan Y., Barks J.D., Silverstein F.S. Bumetanide augments the neuroprotective efficacy of phenobarbital plus hypothermia in a neonatal hypoxia-ischemia model. Pediatr. Res. 2012, 71:559-565.
116. Lopez-Samblas A.M., Adams J.A., Goldberg R.N., Modi M.W. The pharmacokinetics of bumetanide in the newborn infant. Biol. Neonate 1997, 72:265-272.
117. Löscher W., Puskarjov M., Kaila K. Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology 2013, 69:62-74.
118. Luisi S., Petraglia F., Benedetto C., Nappi R.E., Bernardi F., Fadalti M., Reis F.M., Luisi M., Genazzani A.R. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. J. Clin. Endocrinol. Metab. 2000, 85:2429-2433.
119. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:9861-9866.
120. Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:9561-9566.
121. Marshall J.D., Wells T.G., Letzig L., Kearns G.L. Pharmacokinetics and pharmacodynamics of bumetanide in critically ill pediatric patients. J. Clin. Pharmacol. 1998, 38:994-1002.
122. Martinez-Mir M.I., Pollard H., Moreau J., Arrang J.M., Ruat M., Traiffort E., Schwartz J.C., Palacios J.M. Histamine receptor-H1, receptor-H2 and receptor-H3 visualized in the brain of human and nonhuman-primates. Brain Res. 1990, 526:322-327.
123. Matagne A., Margineanu D.-G., Kenda B., Michel P., Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br. J. Pharmacol. 2008, 154:1662-1671.
124. Mazarati A., Lu X., Kilk K., Langel U., Wasterlain C., Bartfai T. Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur. J. Neurosci. 2004, 19:3235-3244.
125. Mazarati A., Lu X., Shinmei S., Badie-Madhavi H., Bartfai T. Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice. Neuroscience 2004, 128:431-441.
126. Mazarati A., Lu X. Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors. Neuropeptides 2005, 39:277-280.
127. McClain R.M., Dammers K.D. Toxicologic evaluation of bumetanide, potent diuretic agent. J. Clin. Pharmacol. 1981, 21:543-554.
128. Meikle L., Talos D.M., Onda H., Pollizzi K., Rotenberg A., Sahin M., Jensen F.E., Kwiatkowski D.J. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J. Neurosci. 2007, 27:5546-5558.
129. 18F]MPPF-PET study. Brain 2004, 127:900-913.
130. Minor R.K., Smith D.L., Sossang A.M., Kaushik S., Poosala S., Spangler E.L., Roth G.S., Lane M., Allison D.B., deCabo R., Ingraham D., Mattison J.A. Chronic ingestion of 2-deoxy-d-glucose induces cardiac vacuolization and increases mortality in rats. Toxicol. Appl. Pharmacol. 2010, 243:332-339.
131. Morrisett R.A., Jope R.S., Snead O.C. Effects of drugs on the initiation and maintenance of status epilepticus induced by administration of pilocarpine to lithium-pretreated rats. Exp. Neurol. 1987, 97:193-200.
132. Muller G. Medicinal chemistry of target family-directed masterkeys. Drug Discov. Today 2003, 8:681-691.
133. Napolioni V., Moavero R., Curatolo P.P. Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain Dev. 2009, 31:104-113.
134. Nicolas J., Tytgat D., Matagne A., Staelens L., Klitgaard H., Kervyn S. High brain permeability differentiates brivaracetam from levetiracetam and reveals promising potential as acute intervention against prolonged and life threatening seizures. Epilepsy Curr. 2014, 14:224.
135. Nicolas J.M., Chanteux H., Rosa M., Watanabe S., Stockis A. Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab. Dispos. 2012, 40:1466-1472.
136. Nowak M., Strzelczyk A., Reif P.S., Schorlemmer K., Bauer S., Norwood B.A., Oertel W.H., Rosenow F., Strik H., Hamer H.M. Minocycline as potent anticonvulsant in a patient with astrocytoma and drug resistant epilepsy. Seizure 2012, 21:227-228.
137. Ockuly J.C., Gielissen J.M., Levenick C.V., Zeal C., Groble K., Munsey K., Sutula T.P., Stafstrom C.E. Behavioral, cognitive, and safety profile of 2-deoxy-2-glucose (2DG) in adult rats. Epilepsy Res. 2012, 101:246-252.
138. O'Donnell A., Faivre S., Burris H.A., Rea D., Papadimitrakopoulou V., Shand N., Lane H.A., Hazell K., Zoellner U., Kovarik J.M., Brock C., Jones S., Raymond E., Judson I. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 2008, 26:1588-1595.
139. Pacifici G.M. Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants. Paediatr. Drugs 2012, 14:233-246.
140. Park P., Schachter S., Yaksh T. Intrathecal huperzine A increases thermal escape latency and decreases flinching behavior in the formalin test in rats. Neurosci. Lett. 2010, 470:6-9.
141. Parshin A., Antonova S., Toumi M., Bakhutashvili A. Beprodone a new potent antiepileptic compound - preclinical pharmacology. 13th European Conference on Epilepsy & Society 2013, (Abstract).
142. Paul S., Purdy R.H. Neuroactive steroids. FASEB J. 1992, 6:2311-2322.
143. Pelliccia A., Grssi G., Romano A., Crocchiolo P. Treatment with CBD in oily solutions of drug-resistant pediatric epilepsies. Congress on Cannabis and the Cannabinoids, Leiden, The Netherlands. International Association for Cannabis as Medicine, Third Conference of Cannabis in Medicine 2005, (Abstract).
144. Perek-Polnik M., Jóźwiak S., Jurkiewicz E., Perek D., Kotulska K. Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex. Eur. J. Paediatr. Neurol. 2011, 16:83-85.
145. Pieribone V.A., Tsai J., Soufflet C., Rey E., Shaw K., Giller E., Dulac O. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia 2007, 48:1870-1874.
146. Pouliot W., Bialer M., Hen N., Shekh-Ahmad T., Kaufmann D., Yagen B., Ricks K., Roach B., Nelson C., Dudek F.E. Electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Neuroscience 2013, 231:145-156.
147. Pressler R.M., Mangum B. Newly emerging therapies for neonatal seizures. Semin. Fetal Neonatal Med. 2013, 18:216-223.
148. Qian B.C., Wang M., Zhou Z.F., Chen K., Zhou R.R., Chen G.S. Pharmacokinetics of tablet huperzine A in six volunteers. Acta Pharmacol. Sin. 1995, 16(3):96-398.
149. Raez L.E., Langmuir V., Tolba K., Rocha-Lima C.M., Papadopoulos K., Kroll S., Brawer M., Rosenblatt J., Ricart A., Lampidis T. Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas. J. Clin. Oncol. 2007, 25(s18):14025.
150. Rafii M.S., Walsh S., Little J.T., Behan K., Reynolds B., Ward C., Jin S., Thomas R., Aisen P.S. Alzheimer's Disease Cooperative Study. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 2011, 76:1389-1394.
151. Reddy D.S., Rogawski M.A. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J. Pharmacol. Exp. Ther. 2000, 295:1241-1248.
152. Reddy D.S., Rogawski M.A. Neurosteroids - endogenous regulators of seizure susceptibility and role in the treatment of epilepsy. Contemporary Neurology Series 2012, vol. 80:984-1002. Oxford University Press, (Chapter 77). fourth ed. J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta (Eds.).
153. Rheims S., Minlebaev M., Ivanov A., Represa A., Khazipov R., Holmes G.L., Ben-Ari Y., Zilberter Y. Excitatory GABA in rodent developing neocortex in vitro. J. Neurophysiol. 2008, 100:609-619.
154. Richerson G.B., Buchanan G.F. The serotonin axis: shared mechanisms in seizures, depression, and SUDEP. Epilepsia 2011, 52(Suppl. 1):28-38.
155. Rickels K., Mathew S., Banov M.D., Zimbroff D.L., Oshana S., Parsons E.C., Donahue S.R., Kauffman M., Iyer G.R., Reinhard J.F. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2008, 28:235-239.
156. Robertson C.R., Scholl E.A., Pruess T.H., Green B.R., White H.S., Bulaj G. Engineering galanin analogues that discriminate between GalR1 and GalR2 subtypes and exhibit anticonvulsant activity following systemic delivery. J. Med. Chem. 2010, 53:1871-1875.
157. Rogawski M.A., Loya C.M., Reddy K., Zolkowska D., Lossin C. Neuroactive steroids for the treatment of status epilepticus. Epilepsia 2013, 54(Suppl. 6):93-98.
158. Rolan P., Sargentini-Maier M.L., Pigeolet E., Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males. Br. J. Clin. Pharmacol. 2008, 66:71-75.
159. Rundfeldt C., Löscher W. The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs 2014, 28:29-43.
160. Rutecki P., Osting S., Langberg T., Sutula T. Therapeutic effects of 2DG at the time of injury on fear conditioning and fear context recall at long intervals after TBI in plasticity-susceptible rats. Poster 628.13 Soc. Neurosci. Abstr. 2013, http://www.sfn.org/.
161. 2+ levels. J. Neurosci. 2009, 29:2053-2063.
162. Ryvlin P., Werhahn K.J., Blaszczyk B., Johnson M.E., Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 2014, 55:47-56.
163. Saar K., Mazarati A.M., Mahlapuu R., Hallnemo G., Soomets U., Kilk K., Hellburg S., Pooga M., Tolf B.R., Shi T.S., Hökfelt T., Wasterlain C., Bartfai T., Langel U. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:7136-7141.
164. Sagratella S. Characterization of the in vitro antiepileptic activity of new and old anticonvulsant drugs. Gen. Pharmacol. 1998, 30:153-160.
165. Sargentini-Maier M.L., Espie P., Coquette A., Stockis A. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab. Dispos. 2008, 36:36-45.
166. Sargentini-Maier M.L., Rolan P., Connell J., Tytgat D., Jacobs T., Pigeolet E., Riethuisen J.M., Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br. J. Clin. Pharmacol. 2007, 63:680-688.
167. Sargentini-Maier M.L., Sokalski A., Boulanger P., Jacobs T., Stockis A. Brivaracetam disposition in renal impairment. J. Clin. Pharmacol. 2012, 52:1927-1933.
168. Savic I., Lindstrom P., Gulyas B., Halldin C., Andree B., Farde L. Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology 2004, 62:1343-1351.
169. Schumacher M., Mattern C., Ghoumari A., Oudinet J.P., Liere P., Labombarda F., Sitruk-Ware R., De Nicola A.F., Guennoun R. Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors. Prog. Neurobiol. 2014, 113:6-39.
170. Schwartz J.C. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br. J. Pharmacol. 2011, 163:713-721.
171. Scutt A., Williamson E.M. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif. Tissue Int. 2007, 80:50-59.
172. Shekh-Ahmad T., Hen N., McDonough J.H., Yagen B., Bialer M. Valnoctamide and sec-propyl-butylacetamide (SPD) for acute seizures and status epielpticus. Epilepsia 2013, 54(Suppl. 5):98-101.
173. Shekh-Ahmad T., Hen N., Yagen B., McDonough J.H., Finnell R.H., Wlodarczyk B., Bialer M. Stereoselective anticonvuslant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia 2014, 55:353-361.
174. Shen H.Y., Singer P., Lytle N., Wei C.J., Lan J.Q., Williams-Karnesky R.L., Chen J.F., Yee B.K., Boison D. Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. J. Clin. Invest. 2012, 122:2567-2577.
175. Singh D., Banerji A.K., Dwarakanath B.S., Tripathi R.P., Gupta J.P., Mathew T.L., Ravindranath T., Jain V. Optimizing cancer radiotherapy with 2-deoxy-d-glucose: dose escalation studies in patients with glioblastoma multiforme. Strahlenther. Onkol. 2005, 181:507-514.
176. Sonnenblick M., Rosin A.J., Weissberg N. Neurological and psychiatric side effects of cimetidine - report of 3 cases with review of the literature. Postgrad. Med. J. 1982, 58:415-418.
177. Spampanato J., Dudek E.F. Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus. Epilepsia 2014, 10.111/epi.12702.
178. Stafstrom C., Ockuly J., Valley M., Roopra A., Sutula T. Novel anticonvulsant and antiepileptic properties of 2-deoxy-d-glucose in experimental epilepsy models. Ann. Neur. 2009, 65:435-448.
179. Stein M., Lin H., Jeyamohan C., Dvorzhinski D., Gounder M., Bray K., Eddy S., Goodin S., White E., DiPaola R.S. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 2010, 70:1388-1394.
180. Steinmetz K.L., Rausch L. Intravenous dose range finding toxicity of allopregnanolone (ALLO) in neonatal dogs. Toxicol. Sci. 2013, 132(a1831):389.
181. Stockis A., Rolan P. Effect of brivaracetam (400mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women. J. Clin. Pharmacol. 2013, 53:1313-1321.
182. Stockis A., Sargentini-Maier M.L., Horsmans Y. Brivaracetam disposition in mild to severe hepatic impairment. J. Clin. Pharmacol. 2013, 53:633-641.
183. Stockis A., Watanabe S., Fauchoux N. Interaction between brivaracetam (100mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. Epilepsia 2014, 55:e27-e31.
184. Stockis A., Watanabe S., Rouits E., Matsuguma K., Irie S. Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype. Drug Metab. Pharmacokinet. 2014, 9:394-399.
185. Sullivan J.E., Witte M.K., Yamashita T.S., Myers C.M., Blumer J.L. Pharmacokinetics of bumetanide in critically ill infants. Clin. Pharmacol. Ther. 1996, 60:405-413.
186. Sun F.J., Guo W., Zheng D.H., Zhang C.Q., Li S., Liu S.Y., Yin Q., Yang H., Shu H.F. Increased expression of TRPV1 in the cortex and hippocampus from patients with mesial temporal lobe epilepsy. J. Mol. Neurosci. 2013, 49:182-193.
187. Sutula T., Franzoso S. Dose-response and time course of action of disease-modifying effects of 2DG on kindling progression: effectiveness of administration after seizures. Epilepsia 2008, 49(Suppl. 7):382.
188. Szybala C., Pritchard E.M., Wilz A., Kaplan D.L., Boison D. Antiepileptic effects of silk-polymer based adenosine release in kindled rats. Exp. Neurol. 2009, 219:126-135.
189. Tang X.C., Han Y.F. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. CNS Drug Rev. 2009, 5:281-300.
190. Taylor R.R., Nevill G., Forge A. Rapid hair cell loss: a mouse model for cochlear lesions. J. Assoc. Res. Otolaryngol. 2008, 9:44-64.
191. Timby E., Balgard M., Nyberg S., Spigset O., Andersson A., Porankiewicz-Asplund J., Purdy R.H., Zhu D., Bäckström T., Poromaa I.S. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl.) 2006, 186:414-424.
192. A receptor agonist, decreases gonadotropin levels in women. A preliminary study. Gynecol. Endocrinol. 2011, 27:1087-1093.
193. Tipold A., Keefe T.J., Löscher W., Rundfeldt C., de Vries F. Clinical efficacy and safety of imepitoin in comparison with phenobarbital for the control of idiopathic epilepsy in dogs. J. Vet. Pharmacol. Ther. 2014, (July). 10.1111/jvp.12151.
194. Tjolsen A., Berge O.G., Hunskaar J., Roseland H.R., Hole K. The formalin test: an evaluation of the method. Pain 1992, 51:5-17.
195. Toczek M.T., Carson R.E., Lang L., Ma Y., Spanaki M.V., Der M.G., Fazilat S., Kopylev L., Herscovitch P., Eckelman W.C., Theodore W.H. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003, 60:749-756.
196. Trembly B., Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana'90 International Conference on Cannabinoids 1990, (abstract).
197. Turmen T., Thom P., Louridas A.T., LeMorvan P., Aranda J.V. Protein binding and bilirubin displacing properties of bumetanide and furosemide. Clin. Pharmacol. 1982, 22:551-556.
198. Tuzel Comparison of adverse reactions to bumetanide and furosemide. J Clin. Pharmacol. 1981, 21:615-619.
199. Vaitkevicius H., Ng M., Moura L., Rosenthal E., Westover M.B., Rosand J., Rogawski M.A., Reddy K., Cole A.J. Successful allopregnanolone treatment of new onset refractory status epilepticus (NORSE) syndrome: first in man experience. Epilepsia 2013, 54(suppl 6):106-124.
200. van Broekhoven F., Bäckström T., van Luijtelaar G., Buitelaar J.K., Smits P., Verke R.J. Effects of allopregnanolone on sedation in men, and in women on oral contraceptives. Psychoneuroendocrinology 2007, 32:555-564.
201. van Paesschen W., Hirsch E., Johnson M., Falter U., von Rosenstiel P. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 2013, 54:89-97.
202. Visser S.A., Gladdines W.W., van der Graaf P.H., Peletier L.A., Danhof M. Neuroactive steroids differ in potency but not in intrinsic efficacy at the GABA(A) receptor in vivo. J. Pharmacol. Exp. Ther. 2002, 303:616-626.
203. Vollner L., Bieniek D., Korte F. Hashish. XX. Cannabidivarin, a new hashish constituent 1969, 145-147. Tetrahedron Lett.
204. von Rosenstiel P., Perucca E. Brivaracetam. The Treatment of Epilepsy 2009, 447-457. Wiley-Blackwell, Chichester. 3rd ed. S. Shorvon, E. Perucca, J. Engel (Eds.).
205. Vyklicky L., Novakova-Tousova K., Benedikt J., Samad A., Touska F., Vlachova V. Calcium-dependent desensitization of vanilloid receptor TRPV1: a mechanism possibly involved in analgesia induced by topical application of capsaicin. Physiol. Res. 2008, 57(Suppl. 3):S59-S68.
206. Walker P.C., Shankaran S. The bilirubin-displacing capacity of bumetanide in critically ill babies. Dev. Pharmacol. Ther. 1988, 11:265-272.
207. Walter L., Stella N. Cannabinoids and neuroinflammation. Br. J. Pharmacol. 2004, 141:775-785.
208. Wang D.D., Englot D.J., Garcia P.A., Lawton M.T., Young W.L. Minocycline- and tetracycline-class antibiotics are protective against partial seizures in vivo. Epilepsy Behav. 2012, 24:314-318.
209. Wang D.D., Kriegstein A.R. GABA regulates excitatory synapse formation in the neocortex via NMDA receptor activation. J. Neurosci. 2008, 28:5547-5558.
210. Ward A., Heel R.C. Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984, 28:426-464.
211. White H.S., Alex A.B., Pollock A., Hen N., Shekh-Ahmed T., Wilcox K.S., McDonough J.H., Stables J.P., Kaufmann D., Yagen B., Bialer M. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 2012, 53:134-146.
212. White H.S., Schachter S., Lee D., Xiaoshen J., Eisenberg D. Anticonvulsant activity of Huperzine A, an alkaloid extract of Chinese club moss (Huperzia serrata). Epilepsia 2005, 46(Suppl. 8):220.
213. Wiegand G., May T.W., Ostertag P., Boor R., Stephani U., Franz D.N. Verolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?. Eur. J. Paediatr. Neurol. 2013, 17:631-638.
214. Wieland S., Lan N.C., Mirasedeghi S., Gee K.W. Anxiolytic activity of the progesterone metabolite 5 alpha-pregnan-3 alpha-o1-20-one. Brain Res. 1991, 565:263-268.
215. Williams-Karnesky R.L., Sandau U.S., Lusardi T.A., Lytle N.K., Farrell J.M., Pritchard E.M., Kaplan D.L., Boison D. Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. J. Clin. Invest. 2013, 123:3552-3563.
216. Wilz A., Pritchard E.M., Li T., Lan J.Q., Kaplan D.L., Boison D. Silk polymer-based adenosine release: therapeutic potential for epilepsy. Biomaterials 2008, 29:3609-3616.
217. Ye J.W., Cai J.X., Wang L.M., Tang X.C. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J. Pharmacol. Exp. Ther. 1999, 288:814-819.
218. Yu D., Thakor D.K., Han I., Ropper A.E., Haragopal H., Sidman R.L., Zafonte R., Schachter S.C., Teng Y.D. Alleviation of chronic pain following rat spinal cord compression injury with multimodal actions of huperzine A. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E746-E755.
219. Zeng L.H., Xu L., Gutmann D.H., Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann. Neurol. 2008, 63:444-453.
220. Zhou J., Tang T. Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons. FEBS Lett. 2002, 526:21-25.
221. Zhou J., Zhang H.Y., Tang X.C. Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci. Lett. 2001, 313:137-140.